CTMX
CytomX Therapeutics, Inc.
$3.76
-0.20 (-4.93%)
At close · Jul 10
Market Cap
$818.56M
Shares
217,702,919
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$76.2M
-44.8%
FY2025
Net Income
-$17.37M
-154.5%
FY2025
Operating Margin
-29.35%
-47.4pp
FY2025
Operating Cash Flow
-$75.59M
+12.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $35.54M | $76.2M | $138.1M | $101.21M | $53.16M | $37.31M | $68.43M | $26.9M | $59.5M | $71.62M | $15.04M | $7.71M | $5.08M | $888K | |
| $69.1M | $68.73M | $83.38M | $77.68M | $111.65M | $114.19M | $112.94M | $131.62M | $103.87M | $92.28M | $54.76M | $28.36M | $28.3M | $10.89M | |
| $31.1M | $29.84M | $29.73M | $30.02M | $42.85M | $39.16M | $36.03M | $36.77M | $33.51M | $25.61M | $19.87M | $12.56M | $6.54M | $4.95M | |
| — | $146K | $146K | $146K | $146K | $146K | $146K | $146K | $146K | $146K | — | — | — | — | |
| — | — | — | — | — | — | — | — | $1.88M | $1.65M | $1.73M | $1.21M | $783K | $655K | |
| $100.2M | $98.57M | $113.11M | $107.7M | $154.5M | $153.35M | $148.97M | $168.38M | $137.38M | $117.88M | $74.63M | $40.92M | $34.84M | $15.84M | |
| -$64.66M | -$22.36M | $25M | -$6.48M | -$101.34M | -$116.04M | -$80.54M | -$141.48M | -$77.87M | -$46.26M | -$59.59M | -$33.2M | -$29.77M | -$14.96M | |
| — | -29.35% | 18.1% | -6.41% | -190.61% | -311% | -117.7% | -525.92% | -130.88% | -64.59% | -396.1% | -430.54% | -586.27% | -1684.23% | |
| — | — | — | — | — | — | — | — | -$75.99M | -$44.61M | -$57.85M | -$32M | -$28.98M | -$14.3M | |
| $1.54M | — | — | — | — | — | — | — | — | — | $1.69M | $1.73M | $487K | $254K | |
| $5.74M | $5.21M | $7.14M | $9.84M | $1.68M | $255K | $1.84M | $8.37M | $7.64M | $2.67M | $736K | $1.32M | $7000 | $6000 | |
| $10K | $28K | -$38K | -$30K | $340K | -$83K | -$27K | -$135K | -$68K | -$27K | -$69K | -$1.74M | -$55K | $71K | |
| -$58.91M | -$17.13M | $32.09M | $3.32M | -$99.32M | -$115.87M | -$78.73M | -$133.25M | -$70.3M | -$43.61M | -$58.92M | -$35.36M | -$30.3M | -$15.13M | |
| $235K | $238K | $224K | $3.89M | $0 | $0 | -$13.91M | -$427K | $14.3M | -$513K | -$19K | $10K | $10K | $10K | |
| -$59.14M | -$17.37M | $31.87M | -$569K | -$99.32M | -$115.87M | -$64.82M | -$132.83M | -$84.6M | -$43.1M | -$58.9M | -$35.37M | -$30.31M | -$15.14M | |
| — | -22.79% | 23.08% | -0.56% | -186.82% | -310.54% | -94.73% | -493.74% | -142.19% | -60.17% | -391.54% | -458.69% | -597.01% | -1705.29% | |
| — | -$20.37M | $31.87M | — | — | — | — | — | — | -$43.1M | -$58.9M | -$42.08M | -$34.88M | -$18.89M | |
| -$59.04M | -$17.28M | $31.8M | -$484K | -$99.07M | -$116.07M | -$64.92M | -$132.68M | -$84.6M | -$43.17M | -$58.85M | -$35.45M | -$30.31M | -$15.14M | |
| shares | — | 137.94M | 84.44M | 73.81M | 65.74M | 64.15M | 46.15M | 45.34M | 41.66M | 37.17M | 36.23M | 8.6M | 989.45K | 772.32K |
| shares | — | 137.94M | 84.75M | 73.81M | 65.74M | 64.15M | 46.15M | 45.34M | 41.66M | 37.17M | 36.23M | 8.6M | 989.45K | 772.32K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.52×